This clinical trial evaluates the addition of CAN-2409 plus prodrug for stage III/IV NSCLC
patients who are on standard of care first line ICI (anti-PD-1/PD-L1) but with evidence of
suboptimal response (either disease progression or stable disease at time of study
enrollment). CAN-2409 plus prodrug has been shown to increase the response rate to ICI in
animal studies. Safety and tolerability of CAN-2409 plus prodrug has been demonstrated in
clinical trials in over 950 patients with cancer, including cancers of the lung, pancreas,
prostate, and brain. Initial proof of mechanism has been shown in non-small lung cancer,
prostate cancer, high-grade glioma, and pancreatic cancer. The eligibility criterion in the
current clinical trial is based on time on ICI and response status with cohorts as follows:
Cohort 1A and 1B: patients with stable disease radiographically at least 18 weeks after
starting ICI treatment and who are clinically stable
Cohort 2A and 2B: patients with evidence of radiographic progression at least 18 weeks after
starting ICI treatment but who are clinically stable.
Cohort 3, which is now closed for enrollment, was for patients who had evidence of
radiographic progression at least 9 weeks after starting ICI but who were clinically stable.
The specific ICI treatment regimen is not specified to allow for different standard of care
options with or without chemotherapy; for example, pembrolizumab alone, pembrolizumab plus
chemotherapy, or atezolizumab/chemotherapy. In addition, it allows stage III patients after
chemoradiation who may be on durvalumab as their standard of care. For example, a stage III
patient may be eligible for cohort 2 if they have radiographic progression but are clinically
stable 18 weeks after starting durvalumab.
The release of Version 05 of the protocol increased enrollment numbers into Cohorts 1 and 2
(from target n=32 evaluable to n=40 evaluable), while closing Cohort 3. In Amendment 6,
cohort 1B and 2B were initiated to evaluate a 3-dose regimen of CAN-2409 + prodrug.
Adjustments to the sample size extended the anticipated primary completion date for this
trial.